Regulation of Nox enzymes expression in vascular pathophysiology: Focusing on transcription factors and epigenetic mechanisms

Redox Biology

Volumn 5, Issue , 2015, Pages 358-366

  Manea, Simona Adriana ^a   Constantin, Alina ^a   Manda, Gina ^b   Sasson, Shlomo ^c   Manea, Adrian ^a  

^a INSTITUTE OF CELLULAR BIOLOGY AND PATHOLOGY NICOLAE SIMIONESCU   (Romania)

^b VICTOR BABES NATIONAL INSTITUTE OF PATHOLOGY   (Romania)

^c HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Cardiovascular diseases; Epigenetics; NADPH oxidase; Transcription factors

Indexed keywords

CARBOHYDRATE DERIVATIVE; CELL NUCLEUS RECEPTOR; NUCLEIC ACID; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; TRANSCRIPTION FACTOR; CELL RECEPTOR;

APOPTOSIS; BIOCHEMISTRY; CARDIOVASCULAR DISEASE; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; DIABETES MELLITUS; ENZYME ACTIVITY; ENZYME MECHANISM; ENZYME REGULATION; EPIGENETICS; GENETIC REGULATION; HUMAN; IMMUNE RESPONSE; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR PATHOLOGY; NERVE DEGENERATION; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DEFECT; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; UPREGULATION; VASCULAR DISEASE; GENETIC EPIGENESIS; GENETICS; METABOLISM; OXIDATIVE STRESS; PATHOLOGY;

CARDIOVASCULAR DISEASES; EPIGENESIS, GENETIC; HUMANS; NADPH OXIDASE; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 84933514292     PISSN: 22132317     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.redox.2015.06.012     Document Type: Review

References (119)

1. Ushio-Fukai M., Zafari A.M., Fukui T., Ishizaka N., Griendling K.K. p22phox is a critical component of the superoxide-generating NADH/NADPH oxidase system and regulates angiotensin II-induced hypertrophy in vascular smooth muscle cells. J. Biol. Chem. 1996, 271:23317-23321.
2. Rajagopalan S., Kurz S., Münzel T., Tarpey M., Freeman B.A., Griendling K.K., Harrison D.G. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J. Clin. Invest. 1996, 97:1916-1923.
3. Warnholtz A., Nickenig G., Schulz E., Macharzina R., Bräsen J.H., Skatchkov M., Heitzer T., Stasch J.P., Griendling K.K., Harrison D.G., Böhm M., Meinertz T., Münzel T. Increased NADH-oxidase-mediated superoxide production in the early stages of atherosclerosis: evidence for involvement of the renin-angiotensin system. Circulation 1999, 99:2027-2033.
4. San Martin A., Griendling K.K. NADPH oxidases: progress and opportunities. Antioxid. Redox Signal. 2014, 20:2692-2694.
5. Altenhöfer S., Radermacher K.A., Kleikers P.W., Wingler K., Schmidt H.H. Evolution of NADPH oxidase inhibitors: selectivity and mechanisms for target engagement. Antioxid. Redox Signal. 2014, 10.1089/ars.2013.5814.
6. Gorin Y., Cavaglieri R.C., Khazim K., Lee D.Y., Bruno F., Thakur S., Fanti P., Szyndralewiez C., Barnes J.L., Block K., Abboud H.E. Targeting NADPH oxidase with a novel dual Nox1/Nox4 inhibitor attenuates renal pathology in type 1 diabetes. Am. J. Physiol. Renal. Physiol. 2015, ajprenal.00396.2014. 10.1152/ajprenal.00396.2014.
7. Gray S.P., Di Marco E., Okabe J., Szyndralewiez C., Heitz F., Montezano A.C., de Haan J.B., Koulis C., El-Osta A., Andrews K.L., Chin-Dusting J.P., Touyz R.M., Wingler K., Cooper M.E., Schmidt H.H., Jandeleit-Dahm K.A. NADPH oxidase 1 plays a key role in diabetes mellitus-accelerated atherosclerosis. Circulation 2013, 127:1888-1902.
8. Selemidis S., Sobey C.G., Wingler K., Schmidt H.H., Drummond G.R. NADPH oxidases in the vasculature: molecular features, roles in disease and pharmacological inhibition. Pharmacol. Ther. 2008, 120:254-291.
9. Touyz R.M., Chen X., Tabet F., Yao G., He G., Quinn M.T., Pagano P.J., Schiffrin E.L. Expression of a functionally active gp91phox-containing neutrophil-type NAD(P)H oxidase in smooth muscle cells from human resistance arteries: regulation by angiotensin II. Circ. Res. 2002, 90:1205-1213.
10. Takeya R., Ueno N., Kami K., Taura M., Kohjima M., Izaki T., Nunoi H., Sumimoto H. Novel human homologues of p47phox and p67phox participate in activation of superoxide-producing NADPH oxidases. J. Biol. Chem. 2003, 278:25234-25246.
11. Viedt C., Fei J., Krieger-Brauer H.I., Brandes R.P., Teupser D., Kamimura M., Katus H.A., Kreuzer J. Role of p22phox in angiotensin II and plateletderived growth factor AA induced activator protein 1 activation in vascular smooth muscle cells. J. Mol. Med. 2004, 82:31-38.
12. Kim J.S., Diebold B.A., Babior B.M., Knaus U.G., Bokoch G.M. Regulation of Nox1 activity via protein kinase A-mediated phosphorylation of NoxA1 and 14-3-3 binding. J. Biol. Chem. 2007, 282:34787-34800.
13. Yamamori T., Inanami O., Nagahata H., Kuwabara M. Phosphoinositide 3-kinase regulates the phosphorylation of NADPH oxidase component p47(phox) by controlling cPKC/PKCdelta but not Akt. Biochem. Biophys. Res. Commun. 2004, 316:720-730.
14. Kilpatrick L.E., Sun S., Li H., Vary T.C., Korchak H.M. Regulation of TNF-induced oxygen radical production in human neutrophils: role of delta-PKC. J. Leukoc. Biol. 2010, 87:153-164.
15. Kim Y.S., Morgan M.J., Choksi S., Liu Z.G. TNF-induced activation of the Nox1 NADPH oxidase and its role in the induction of necrotic cell death. Mol. Cell 2007, 26:675-687.
16. Gianni D., Bohl B., Courtneidge S.A., Bokoch G.M. The involvement of the tyrosine kinase c-Src in the regulation of reactive oxygen species generation mediated by NADPH oxidase-1. Mol. Biol. Cell 2008, 19:2984-2994.
17. Fenyo I.M., Florea I.C., Raicu M., Manea A. Tyrphostin AG490 reduces NAPDH oxidase activity and expression in the aorta of hypercholesterolemic apolipoprotein E-deficient mice. Vascul. Pharmacol. 2011, 54:100-106.
18. Chen F., Yu Y., Haigh S., Johnson J., Lucas R., Stepp D.W., Fulton D.J. Regulation of NADPH oxidase 5 by protein kinase C isoforms. PLoS One 2014, 9:e88405.
19. Janiszewski M., Lopes L.R., Carmo A.O., Pedro M.A., Brandes R.P., Santos C.X., Laurindo F.R. Regulation of NAD(P)H oxidase by associated protein disulfide isomerase in vascular smooth muscle cells. J. Biol. Chem. 2005, 280(49):40813-40819.
20. Miller F.J., Filali M., Huss G.J., Stanic B., Chamseddine A., Barna T.J., Lamb F.S. Cytokine activation of nuclear factor kappa B in vascular smooth muscle cells requires signaling endosomes containing Nox1 and ClC-3. Circ. Res. 2007, 101:663-671.
21. Pandey D., Gratton J.P., Rafikov R., Black S.M., Fulton D.J. Calcium/calmodulin-dependent kinase II mediates the phosphorylation and activation of NADPH oxidase 5. Mol. Pharmacol. 2011, 80:407-415.
22. Sorescu D., Weiss D., Lassègue B., Clempus R.E., Szöcs K., Sorescu G.P., Valppu L., Quinn M.T., J.D.Lambeth, J.D.Vega, W.R.Taylor, K.K.Griendling Superoxide production and expression of nox family proteins in human atherosclerosis. Circulation 2002, 105:1429-1435.
23. Hassler M.R., Egger G. Epigenomics of cancer-emerging new concepts. Biochimie 2012, 94:2219-2230.
24. BelAiba R.S., Djordjevic T., Petry A., Diemer K., Bonello S., Banfi B., Hess J., Pogrebniak A., Bickel C., Görlach A. NOX5 variants are functionally active in endothelial cells. Free Radic. Biol. Med. 2007, 42:446-459.
25. Manea A., Simionescu M. Nox enzymes and oxidative stress in atherosclerosis. Front. Biosci. (Schol Ed.) 2012, 4:651-670.
26. Manea A., Manea S.A., Gan A.M., Constantin A., Fenyo I.M., Raicu M., Muresian H., Simionescu M. Human monocytes and macrophages express NADPH oxidase 5; a potential source of reactive oxygen species in atherosclerosis. Biochem. Biophys. Res. Commun. 2015, 461:172-179.
27. Moreno M.U., San José G., Orbe J., Páramo J.A., Beloqui O., Díez J., Zalba G. Preliminary characterisation of the promoter of the human p22(phox) gene: identification of a new polymorphism associated with hypertension. FEBS Lett. 2003, 542:27-31.
28. Rada B., Leto T.L. Oxidative innate immune defenses by Nox/Duox family NADPH oxidases. Contrib. Microbiol. 2008, 15:164-187.
29. Savina A., Jancic C., Hugues S., Guermonprez P., Vargas P., Moura I.C., Lennon-Duménil A.M., Seabra M.C., Raposo G., Amigorena S. NOX2 controls phagosomal pH to regulate antigen processing during crosspresentation by dendritic cells. Cell 2006, 126:205-218.
30. Jackson S.H., Devadas S., Kwon J., Pinto L.A., Williams M.S. T cells express a phagocyte-type NADPH oxidase that is activated after T cell receptor stimulation. Nat. Immunol. 2004, 5:818-827.
31. Ma J., Becker C., Lowell C.A., Underhill D.M. Dectin-1-triggered recruitment of light chain 3 protein to phagosomes facilitates major histocompatibility complex class II presentation of fungal-derived antigens. J. Biol. Chem. 2012, 287:34149-34156.
32. Crotzer V.L., Matute J.D., Arias A.A., Zhao H., Quilliam L.A., Dinauer M.C., Blum J.S. Cutting edge: NADPH oxidase modulates MHC class II antigen presentation by B cells. J. Immunol. 2012, 189:3800-3804.
33. Eklund E.A., Kakar R. Recruitment of CREB-binding protein by PU.1, IFN-regulatory factor-1, and the IFN consensus sequence-binding protein is necessary for IFN-gamma-induced p67phox and gp91phox expression. J. Immunol. 1999, 163:6095-6105.
34. Kakar R., Kautz B., Eklund E.A. JAK2 is necessary and sufficient for interferon-gamma-induced transcription of the gene encoding gp91PHOX. J. Leukoc. Biol. 2005, 77:120-127.
35. Lindsey S., Zhu C., Lu Y.F., Eklund E.A. HoxA10 represses transcription of the gene encoding p67phox in phagocytic cells. J. Immunol. 2005, 175:5269-5279.
36. Celada A., Borràs F.E., Soler C., Lloberas J., Klemsz M., van Beveren C., McKercher S., Maki R.A. The transcription factor PU.1 is involved in macrophage proliferation. J. Exp. Med. 1996, 184:61-69.
37. Maruyama S., Kanoh M., Matsumoto A., Kuwahara M., Yamashita M., Asano Y. A novel function of interferon regulatory factor-1: inhibition of Th2 cells by down-regulating the Il4 gene during Listeria infection. Int. Immunol. 2015, 27:143-152.
38. Shi L., Perin J.C., Leipzig J., Zhang Z., Sullivan K.E. Genome-wide analysis of interferon regulatory factor I binding in primary human monocytes. Gene 2011, 487:21-28.
39. Gareus R., Kotsaki E., Xanthoulea S., van der Made I., Gijbels M.J., Kardakaris R., Polykratis A., Kollias G., de Winther M.P., Pasparakis M. Endothelial cell-specific NF-kappaB inhibition protects mice from atherosclerosis. Cell Metab. 2008, 8:372-383.
40. Manea S.A., Manea A., Heltianu C. Inhibition of JAK/STAT signaling pathway prevents high-glucose-induced increase in endothelin-1 synthesis in human endothelial cells. Cell Tissue Res. 2010, 340:71-79.
41. Recio C., Oguiza A., Lazaro I., Mallavia B., Egido J., Gomez-Guerrero C. Suppressor of cytokine signaling 1-derived peptide inhibits Janus kinase/signal transducers and activators of transcription pathway and improves inflammation and atherosclerosis in diabetic mice. Arterioscler. Thromb. Vasc. Biol. 2014, 34:1953-1960.
42. Sozen E., Karademir B., Yazgan B., Bozaykut P., Ozer N.K. Potential role of proteasome on c-jun related signaling in hypercholesterolemia induced atherosclerosis. Redox Biol. 2014, 2:732-738.
43. de Winther M.P., Kanters E., Kraal G., Hofker M.H. Nuclear factor kappaB signaling in atherogenesis. Arterioscler. Thromb. Vasc. Biol. 2005, 25:904-914.
44. Anrather J., Racchumi G., Iadecola C. NF-kappaB regulates phagocytic NADPH oxidase by inducing the expression of gp91phox. J. Biol. Chem. 2006, 281:5657-5667.
45. Gauss K.A., Nelson-Overton L.K., Siemsen D.W., Gao Y., DeLeo F.R., Quinn M.T. Role of NF-kappaB in transcriptional regulation of the phagocyte NADPH oxidase by tumor necrosis factor-alpha. J. Leukoc. Biol. 2007, 82:729-741.
46. Manea A., Manea S.A., Gafencu A.V., Raicu M. Regulation of NADPH oxidase subunit p22(phox) by NF-kB in human aortic smooth muscle cells. Arch. Physiol. Biochem. 2007, 113:163-172.
47. Manea A., Tanase L.I., Raicu M., Simionescu M. Transcriptional regulation of NADPH oxidase isoforms, Nox1 and Nox4, by nuclear factor-kappaB in human aortic smooth muscle cells. Biochem. Biophys. Res. Commun. 2010, 396:901-907.
48. Izumi Y., Kim S., Zhan Y., Namba M., Yasumoto H., Iwao H. Important role of angiotensin II-mediated c-Jun NH(2)-terminal kinase activation in cardiac hypertrophy in hypertensive rats. Hypertension 2000, 36:511-516.
49. Ahn J.D., Morishita R., Kaneda Y., Lee S.J., Kwon K.Y., Choi S.Y., Lee K.U., Park J.Y., Moon I.J., Park J.G., Yoshizumi M., Ouchi Y., Lee I.K. Inhibitory effects of novel AP-1 decoy oligodeoxynucleotides on vascular smooth muscle cell proliferation in vitro and neointimal formation in vivo. Circ. Res. 2002, 90:1325-1332.
50. Manea A., Manea S.A., Gafencu A.V., Raicu M., Simionescu M. AP-1-dependent transcriptional regulation of NADPH oxidase in human aortic smooth muscle cells: role of p22phox subunit. Arterioscler. Thromb. Vasc. Biol. 2008, 28:878-885.
51. Manea A., Manea S.A., Florea I.C., Luca C.M., Raicu M. Positive regulation of NADPH oxidase 5 by proinflammatory-related mechanisms in human aortic smooth muscle cells. Free Radic. Biol. Med. 2012, 52:1497-1507.
52. Cevik M.O., Katsuyama M., Kanda S., Kaneko T., Iwata K., Ibi M., Matsuno K., Kakehi T., Cui W., Sasaki M., Yabe-Nishimura C. The AP-1 site is essential for the promoter activity of NOX1/NADPH oxidase, a vascular superoxide-producing enzyme: possible involvement of the ERK1/2-JunB pathway. Biochem. Biophys. Res. Commun. 2008, 374:351-355.
53. Manea A., Tanase L.I., Raicu M., Simionescu M. Jak/STAT signaling pathway regulates nox1 and nox4-based NADPH oxidase in human aortic smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 2010, 30:105-112.
54. Kelkenberg U., Wagner A.H., Sarhaddar J., Hecker M., von der Leyen H.E. CCAAT/enhancer-binding protein decoy oligodeoxynucleotide inhibition of macrophage-rich vascular lesion formation in hypercholesterolemic rabbits. Arterioscler. Thromb. Vasc. Biol. 2002, 22:949-954.
55. Zhou A.X., Wang X., Lin C.S., Han J., Yong J., Nadolski M.J., Boren J., Kaufman R.J., Tabas I. C/EBP-homologous protein (CHOP) in vascular smooth muscle cells regulates their proliferation in aortic explants and atherosclerotic lesions. Circ. Res. 2015, 114:305602. CIRCRESAHA.114.305602.
56. Cardinaux J.R., Allaman I., Magistretti P.J. Pro-inflammatory cytokines induce the transcription factors C/EBPbeta and C/EBPdelta in astrocytes. Glia 2000, 29:91-97.
57. Ramji D.P., Foka P. CCAAT/enhancer-binding proteins: structure, function and regulation. Biochem. J. 2002, 365:561-575.
58. Manea S.A., Todirita A., Manea A. High glucose-induced increased expression of endothelin-1 in human endothelial cells is mediated by activated CCAAT/enhancer-binding proteins. PLoS One 2013, 8:e84170.
59. Manea S.A., Todirita A., Raicu M., Manea A. C/EBP transcription factors regulate NADPH oxidase in human aortic smooth muscle cells. J. Cell. Mol. Med. 2014, 18:1467-1477.
60. San José G., Moreno M.U., Oliván S., Beloqui O., Fortuño A., Díez J., Zalba G. Functional effect of the p22phox-930A/G polymorphism on p22phox expression and NADPH oxidase activity in hypertension. Hypertension 2004, 44:163-169.
61. Maitra U., Singh N., Gan L., Ringwood L., Li L. IRAK-1 contributes to lipopolysaccharide-induced reactive oxygen species generation in macrophages by inducing NOX-1 transcription and Rac1 activation and suppressing the expression of antioxidative enzymes. J. Biol. Chem. 2009, 284:35403-35411.
62. Katsuyama M., Fan C., Arakawa N., Nishinaka T., Miyagishi M., Taira K., Yabe-Nishimura C. Essential role of ATF-1 in induction of NOX1, a catalytic subunit of NADPH oxidase: involvement of mitochondrial respiratory chain. Biochem. J. 2005, 386:255-261.
63. Ni W., Zhan Y., He H., Maynard E., Balschi J.A., Oettgen P. Ets-1 is a critical transcriptional regulator of reactive oxygen species and p47(phox) gene expression in response to angiotensin II. Circ. Res. 2007, 101:985-994.
64. Zhang L., Sheppard O.R., Shah A.M., Brewer A.C. Positive regulation of the NADPH oxidase NOX4 promoter in vascular smooth muscle cells by E2F. Free Radic. Biol. Med. 2008, 45:679-685.
65. Plutzky J. The PPAR-RXR transcriptional complex in the vasculature: energy in the balance. Circ. Res. 2011, 108:1002-1016.
66. Balakumar P., Rose M., Singh M. PPAR ligands: are they potential agents for cardiovascular disorders?. Pharmacology 2007, 80:1-10.
67. Calkin A.C., Cooper M.E., Jandeleit-Dahm K.A., Allen T.J. Gemfibrozil decreases atherosclerosis in experimental diabetes in association with a reduction in oxidative stress and inflammation. Diabetologia 2006, 49:766-774.
68. Quintela A.M., Jiménez R., Gómez-Guzmán M., Zarzuelo M.J., Galindo P., Sánchez M., Vargas F., Cogolludo A., Tamargo J., Pérez-Vizcaíno F., Duarte J. Activation of peroxisome proliferator-activated receptor-β/-δ (PPARβ/δ) prevents endothelial dysfunction in type 1 diabetic rats. Free Radic. Biol. Med. 2012, 53:730-741.
69. Tordjman K.M., Semenkovich C.F., Coleman T., Yudovich R., Bak S., Osher E., Vechoropoulos M., Stern N. Absence of peroxisome proliferator-activated receptor-alpha abolishes hypertension and attenuates atherosclerosis in the Tsukuba hypertensive mouse. Hypertension 2007, 50:945-951.
70. Teissier E., Nohara A., Chinetti G., Paumelle R., Cariou B., Fruchart J.C., Brandes R.P., Shah A., Staels B. Peroxisome proliferator-activated receptor alpha induces NADPH oxidase activity in macrophages, leading to the generation of LDL with PPAR-alpha activation properties. Circ. Res. 2004, 95:1174-1182.
71. Sharifpanah F., Wartenberg M., Hannig M., Piper H.M., Sauer H. Peroxisome proliferator-activated receptor alpha agonists enhance cardiomyogenesis of mouse ES cells by utilization of a reactive oxygen species-dependent mechanism. Stem Cells 2008, 26:64-71.
72. Yagil C., Yagil Y. Peroxisome proliferator-activated receptor alpha:friend or foe?. Hypertension 2007, 50:847-850.
73. Chinetti G., Fruchart J.C., Staels B. Peroxisome proliferator-activated receptors (PPARs): nuclear receptors with functions in the vascular wall. Z. Kardiol. 2001, 90:125-132.
74. Riahi Y., Cohen G., Shamni O., Sasson S. Signaling and cytotoxic functions of 4-hydroxyalkenals. Am. J. Physiol. Endocrinol. Metab. 2010, 299:E879-E886.
75. Riahi Y., Sin-Malia Y., Cohen G., Alpert E., Gruzman A., Eckel J., Staels B., Guichardant M., Sasson S. The natural protective mechanism against hyperglycemia in vascular endothelial cells: roles of the lipid peroxidation product 4-hydroxydodecadienal and peroxisome proliferator-activated receptor delta. Diabetes 2010, 59:808-818.
76. Cohen G., Riahi Y., Shamni O., Guichardant M., Chatgilialoglu C., Ferreri C., Kaiser N., Sasson S. Role of lipid peroxidation and PPAR-δ in amplifying glucose-stimulated insulin secretion. Diabetes 2011, 60:2830-2842.
77. Manea A., Manea S.A., Todirita A., Albulescu I.C., Raicu M., Sasson S., Simionescu M. High-glucose-increased expression and activation of NADPH oxidase in human vascular smooth muscle cells is mediated by 4-hydroxynonenal-activated PPARα and PPARβ/δ. Cell Tissue Res. 2015, Feb 27. 10.1007/s00441-015-2120-0.
78. Gizard F., Amant C., Barbier O., Bellosta S., Robillard R., Percevault F., Sevestre H., Krimpenfort P., Corsini A., Rochette J., Glineur C., Fruchart J.C., Torpier G., Staels B. PPAR alpha inhibits vascular smooth muscle cell proliferation underlying intimal hyperplasia by inducing the tumor suppressor p16INK4a. J. Clin. Invest. 2005, 115:3228-3238.
79. Okazaki M., Iwasaki Y., Nishiyama M., Taguchi T., Tsugita M., Nakayama S., Sevestre H., Krimpenfort P., Corsini A., Rochette J., Glineur C., Fruchart J.C., Torpier G., Staels B. PPARbeta/delta regulates the human SIRT1 gene transcription via Sp1. Endocrine J. 2010, 57:403-413.
80. Wolin M.S., Ahmad M., Gupte S.A. Oxidant and redox signaling in vascular oxygen sensing mechanisms: basic concepts, current controversies, and potential importance of cytosolic NADPH. Am. J. Physiol. Lung Cell. Mol. Physiol. 2005, 289:L159-L173.
81. Goyal P., Weissmann N., Grimminger F., Hegel C., Bader L., Rose F., Fink L., Ghofrani H.A., Schermuly R.T., Schmidt H.H., Seeger W., Hänze J. Upregulation of NAD(P)H oxidase 1 in hypoxia activates hypoxia-inducible factor 1 via increase in reactive oxygen species. Free Radic. Biol. Med. 2004, 36:1279-1288.
82. Bonello S., Zähringer C., BelAiba R.S., Djordjevic T., Hess J., Michiels C., Kietzmann T., Görlach A. Reactive oxygen species activate the HIF-1alpha promoter via a functional NFkappaB site. Arterioscler. Thromb. Vasc. Biol. 2007, 27:755-761.
83. Diebold I., Petry A., Hess J., Görlach A. The NADPH oxidase subunit NOX4 is a new target gene of the hypoxia-inducible factor-1. Mol. Biol. Cell 2010, 21:2087-2096.
84. Diebold I., Petry A., Sabrane K., Djordjevic T., Hess J., Görlach A. The HIF1 target gene NOX2 promotes angiogenesis through urotensin-II. J. Cell Sci. 2012, 125:956-964.
85. Cooper M.E., El-Osta A. Epigenetics: mechanisms and implications for diabetic complications. Circ. Res. 2010, 107:1403-1413.
86. Chen S., Feng B., George B., Chakrabarti R., Chen M., Chakrabarti S. Transcriptional coactivator p300 regulates glucose-induced gene expression in endothelial cells. Am. J. Physiol. Endocrinol. Metab. 2010, 298:E127-E137.
87. Okabe J., Orlowski C., Balcerczyk A., Tikellis C., Thomas M.C., Cooper M.E., El-Osta A. Distinguishing hyperglycemic changes by Set7 in vascular endothelial cells. Circ. Res. 2012, 110:1067-1076.
88. Paneni F., Costantino S., Battista R., Castello L., Capretti G., Chiandotto S., Scavone G., Villano A., Pitocco D., Lanza G., Volpe M., Lüscher T.F., Cosentino F. Adverse epigenetic signatures by histone methyltransferase set7 contribute to vascular dysfunction in patients with type 2 diabetes. Circ. Cardiovasc. Genet. 2014, 114:000671. pii: CIRCGENETICS.114.000671.
89. Paneni F., Costantino S., Volpe M., Lüscher T.F., Cosentino F. Epigenetic signatures and vascular risk in type 2 diabetes: a clinical perspective. Atherosclerosis 2013, 230:191-197.
90. Hayes P., Knaus U.G. Balancing reactive oxygen species in the epigenome: NADPH oxidases as target and perpetrator. Antioxid. Redox Signal. 2013, 18:1937-1945.
91. Luxen S., Belinsky S.A., Knaus U.G. Silencing of DUOX NADPH oxidases by promoter hypermethylation in lung cancer. Cancer Res. 2008, 68:1037-1045.
92. Biterge B., Schneider R. Histone variants: key players of chromatin. Cell Tissue Res. 2014, 356:457-466.
93. Vogel T., Lassmann S. Epigenetics: development, dynamics and disease. Cell Tissue Res. 2014, 356:451-455.
94. Wierda R.J., Geutskens S.B., Jukema J.W., Quax P.H., van den Elsen P.J. Epigenetics in atherosclerosis and inflammation. J. Cell. Mol. Med. 2010, 14:1225-1240.
95. Usui T., Okada M., Mizuno W., Oda M., Ide N., Morita T., Hara Y., Yamawaki H. HDAC4 mediates development of hypertension via vascular inflammation in spontaneous hypertensive rats. Am. J. Physiol. Heart Circ. Physiol. 2012, 302:H1894-H1904.
96. Nührenberg T., Gilsbach R., Preissl S., Schnick T., Hein L. Epigenetics in cardiac development, function, and disease. Cell Tissue Res. 2014, 356:585-600.
97. Eom G.H., Nam Y.S., Oh J.G., Choe N., Min H.K., Yoo E.K., Kang G., Nguyen V.H., Min J.J., Kim J.K., Lee I.K., Bassel-Duby R., Olson E.N., Park W.J., Kook H. Regulation of acetylation of histone deacetylase 2 by p300/CBP-associated factor/histone deacetylase 5 in the development of cardiac hypertrophy. Circ Res. 2014, 114:1133-1143.
98. Turgeon P.J., Sukumar A.N., Marsden P.A. Epigenetics of cardiovascular disease - a New "Beat" in coronary artery disease. Med. Epigenet. 2014, 2:37-52.
99. Wang Y., Miao X., Liu Y., Li F., Liu Q., Sun J., Cai L. Dysregulation of histone acetyltransferases and deacetylases in cardiovascular diseases. Oxid. Med. Cell. Longev.. 641979 2014, 2014.
100. Verma M., Banerjee H.N. Epigenetic inhibitors. Methods Mol. Biol. 2015, 1238:469-485.
101. Li X., Xu W. HDAC1/3 dual selective inhibitors - new therapeutic agents for the potential treatment of cancer. Drug. Discov. Ther. 2014, 8:225-228.
102. Lakshmaiah K.C., Jacob L.A., Aparna S., Lokanatha D., Saldanha S.C. Epigenetic therapy of cancer with histone deacetylase inhibitors. J. Cancer Res. Ther. 2014, 10:469-478.
103. Findeisen H.M., Gizard F., Zhao Y., Qing H., Heywood E.B., Jones K.L., Cohn D., Bruemmer D. Epigenetic regulation of vascular smooth muscle cell proliferation and neointima formation by histone deacetylase inhibition. Arterioscler. Thromb. Vasc. Biol. 2011, 31:851-860.
104. Usui T., Morita T., Okada M., Yamawaki H. Histone deacetylase 4 controls neointimal hyperplasia via stimulating proliferation and migration of vascular smooth muscle cells. Hypertension 2014, 63:397-403.
105. Xie M., Kong Y., Tan W., May H., Battiprolu P.K., Pedrozo Z., Wang Z.V., Morales C., Luo X., Cho G., Jiang N., Jessen M.E., Warner J.J., Lavandero S., Gillette T.G., Turer A.T., Hill J.A. Histone deacetylase inhibition blunts ischemia/reperfusion injury by inducing cardiomyocyte autophagy. Circulation 2014, 129:1139-1151.
106. Siuda D., Zechner U., El Hajj N., Prawitt D., Langer D., Xia N., Horke S., Pautz A., Kleinert H., Förstermann U., Li H. Transcriptional regulation of Nox4 by histone deacetylases in human endothelial cells. Basic Res. Cardiol. 2012, 107:283.
107. Zelko I.N., Folz R.J. Regulation of oxidative stress in pulmonary artery endothelium: modulation of EC-SOD and NOX4 expression using HDAC class I inhibitors. Am. J. Respir. Cell Mol. Biol. 2015, 10.1165/rcmb.2014-0260OC.
108. Quivy V., Van Lint C. Regulation at multiple levels of NF-kappaB-mediated transactivation by protein acetylation. Biochem. Pharmacol. 2004, 68:1221-1229.
109. Zarzuelo M.J., López-Sepúlveda R., Sánchez M., Romero M., Gómez-Guzmán M., Ungvary Z., Pérez-Vizcaíno F., Jiménez R., Duarte J. SIRT1 inhibits NADPH oxidase activation and protects endothelial function in the rat aorta: implications for vascular aging. Biochem. Pharmacol. 2013, 85:1288-1296.
110. Gano L.B., Donato A.J., Pasha H.M., Hearon C.M., Sindler A.L., Seals D.R. The SIRT1 activator SRT1720 reverses vascular endothelial dysfunction, excessive superoxide production, and inflammation with aging in mice. Am. J. Physiol. Heart Circ. Physiol. 2014, 307:H1754-H1763.
111. Kawai Y., Arinze I.J. Valproic acid-induced gene expression through production of reactive oxygen species. Cancer Res. 2006, 66:6563-6569.
112. Zhao T.C., Zhang L.X., Cheng G., Liu J.T. gp-91 mediates histone deacetylase inhibition-induced cardioprotection. Biochim. Biophys. Acta 2010, 1803:872-880.
113. Sanders Y.Y., Liu H., Liu G., Thannickal V.J. Epigenetic mechanisms regulate NADPH oxidase-4 expression in cellular senescence. Free Radic. Biol. Med. 2014, 79C:197-205.
114. He M., Zhang B., Wei X., Wang Z., Fan B., Du P., Zhang Y., Jian W., Chen L., Wang L., Fang H., Li X., Wang P.A., Yi F. HDAC4/5-HMGB1 signalling mediated by NADPH oxidase activity contributes to cerebral ischaemia/reperfusion injury. J. Cell. Mol. Med. 2013, 17:531-542.
115. Matsushima S., Kuroda J., Ago T., Zhai P., Park J.Y., Xie L.H., Tian B., Sadoshima J. Increased oxidative stress in the nucleus caused by Nox4 mediates oxidation of HDAC4 and cardiac hypertrophy. Circ. Res. 2013, 112:651-663.
116. Najafi-Shoushtari S.H. MicroRNAs in cardiometabolic disease. Curr. Atheroscler. Rep. 2011, 13:202-207.
117. Fu Y., Zhang Y., Wang Z., Wang L., Wei X., Zhang B., Wen Z., Fang H., Pang Q., Yi F. Regulation of NADPH oxidase activity is associated with miRNA-25-mediated NOX4 expression in experimental diabetic nephropathy. Am. J. Nephrol. 2010, 32:581-589.
118. Varga Z.V., Kupai K., Szucs G., Gáspár R., Pálóczi J., Faragó N., Zvara A., Puskás L.G., Rázga Z., Tiszlavicz L., Bencsik P., Görbe A., Csonka C., Ferdinandy P., Csont T. MicroRNA-25-dependent up-regulation of NADPH oxidase 4 (NOX4) mediates hypercholesterolemia-induced oxidative/nitrative stress and subsequent dysfunction in the heart. J. Mol. Cell Cardiol. 2013, 62:111-121.
119. Ranjan R., Lee Y.G., Karpurapu M., Syed M.A., Chung S., Deng J., Jeong J.J., Zhao G., Xiao L., Sadikot R.T., Weiss M.J., Christman J.W., Park G.Y. p47phox and reactive oxygen species production modulate expression of microRNA-451 in macrophages. Free Radic. Res. 2015, 49:25-34.